recurrent acute myeloid leukemia
Showing 26 - 50 of 66
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia
Recruiting
- Acute Lymphoblastic Leukemia
- +11 more
- Cyclosporine
- +8 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 29, 2022
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (procedure, drug, biological)
Recruiting
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Allogeneic Hematopoietic Stem Cell Transplantation
- +7 more
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (8-Chloroadenosine,
Recruiting
- Acute Myeloid Leukemia
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Aug 15, 2022
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Decitabine, Navitoclax, Venetoclax)
Recruiting
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Decitabine
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Aug 15, 2022
Blasts More Than 20 Percent of Bone Marrow Nucleated Cells, Blasts More Than 20 Percent of Peripheral Blood White Cells,
Completed
- Blasts More Than 20 Percent of Bone Marrow Nucleated Cells
- +4 more
- Decitabine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jul 18, 2022
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute
Active, not recruiting
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- +2 more
-
Columbus, Ohio
- +2 more
Aug 10, 2022
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Newcastle (Bisantrene DiHCl
Recruiting
- Acute Myeloid Leukemia
- +4 more
- Bisantrene Dihydrochloride (high dose)
- +3 more
-
Newcastle, New South Wales, AustraliaCalvary Mater
Jul 14, 2022
Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia With
Active, not recruiting
- Previously Treated Myelodysplastic Syndrome
- +7 more
- Decitabine
- Ipilimumab
-
Duarte, California
- +10 more
Jul 2, 2022
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Cobimetinib, Enasidenib Mesylate)
Not yet recruiting
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Cobimetinib
- Enasidenib Mesylate
-
Duarte, CaliforniaCity of Hope Medical Center
Jun 28, 2022
Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia Trial in
Recruiting
- Recurrent Acute Lymphoblastic Leukemia
- +3 more
- Decitabine
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jun 29, 2022
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Decitabine and
Recruiting
- Acute Myeloid Leukemia
- +2 more
- Decitabine and Cedazuridine
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jun 29, 2022
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Trial in
Completed
- Recurrent Acute Leukemia of Ambiguous Lineage
- +5 more
- Chemosensitivity Assay
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jun 29, 2022
Recurrent Acute Myeloid Leukemia Trial in Duarte (Bosutinib Monohydrate, Decitabine, Enasidenib Mesylate)
Withdrawn
- Recurrent Acute Myeloid Leukemia
- Bosutinib Monohydrate
- +6 more
-
Duarte, CaliforniaCity of Hope Meidcal Center
Jun 7, 2022
Refractory Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia Trial in Kansas City, Baltimore (Fosciclopirox,
Recruiting
- Refractory Acute Myeloid Leukemia
- Recurrent Acute Myeloid Leukemia
- Fosciclopirox
- Fosciclopirox + Cytarabine
-
Kansas City, Kansas
- +1 more
May 28, 2022
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Portland (Decitabine and
Not yet recruiting
- Acute Myeloid Leukemia
- +2 more
- Decitabine and Cedazuridine
- +2 more
-
Portland, OregonOHSU Knight Cancer Institute
May 25, 2022
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells Trial in
Recruiting
- Acute Myeloid Leukemia
- +7 more
- Azacitidine
- +3 more
-
New Brunswick, New JerseyRutgers Cancer Institute of New Jersey
May 16, 2022
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia Trial in Houston (Decitabine and
Recruiting
- Acute Myeloid Leukemia
- +3 more
- Decitabine and Cedazuridine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Apr 19, 2022
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Decitabine and
Recruiting
- Acute Myeloid Leukemia
- +2 more
- Decitabine and Cedazuridine
- Venetoclax
-
Houston, TexasM D Anderson Cancer Center
Apr 1, 2022
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia Trial in Duarte (Decitabine, Pembrolizumab,
Recruiting
- Acute Myeloid Leukemia
- +5 more
- Decitabine
- +2 more
-
Duarte, CaliforniaCity of Hope Comprehensive Cancer Center
Mar 9, 2022
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia Trial in Los Angeles, Sacramento, Oklahoma City (Azacitidine,
Recruiting
- Acute Myeloid Leukemia
- Recurrent Acute Myeloid Leukemia
- Azacitidine
- +2 more
-
Los Angeles, California
- +2 more
Mar 11, 2022
Allogeneic Stem Cell Transplant Recipient, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Recurrent Acute Myeloid
Recruiting
- Allogeneic Stem Cell Transplant Recipient
- +3 more
- Cytarabine Hydrochloride
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Feb 7, 2022
Hematopoietic and Lymphoid Cell Tumor, High Risk Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome Trial in Houston
Active, not recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- +13 more
- Allogeneic Hematopoietic Stem Cell Transplantation
- +9 more
-
Houston, TexasM D Anderson Cancer Center
Feb 8, 2022
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Anti-OX40 Agonist Monoclonal Antibody
Active, not recruiting
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Anti-OX40 Agonist Monoclonal Antibody PF-04518600
- +6 more
-
Houston, TexasM D Anderson Cancer Center
Jan 25, 2022
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Allogeneic Hematopoietic Stem Cell
Completed
- Acute Lymphoblastic Leukemia in Remission
- +6 more
- Allogeneic Bone Marrow Transplantation
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Dec 15, 2021
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Portland (Edicotinib, Pharmacokinetic Study)
Terminated
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Edicotinib
- Pharmacokinetic Study
-
Portland, OregonOHSU Knight Cancer Institute
Dec 1, 2021